Related Stories
Progress
For Sopharma AD this effort is another contribution to an excellent corporate governance file.
Sopharma can be compared with other companies in the Europe. Below is a comparison between the different main companies which highlights their operating performance from the annual consolidated audited report for 2016.
| Indicator (BGN '000) | Sopharma |
KRKA (Slovenia) | Alkaloid** (Macedonia) | Richter Gedeon (Hungary) | Pharmastandard* (Russia) | Stada (Germany) |
|---|---|---|---|---|---|---|
| Sales | 877,085 | 600,473 | 264,117 | 639,728 | 1,870,445 | 1,093,766 |
| EBITDA | 73,656 | 116,969 | 148,581 | |||
| Operating profit | 44,951 | 62,600 | 27,214 | 91,930 | 469,697 | 91,073 |
| Net profit | 54,902 | 55,453 | 23,308 | 109,877 | 242,402 | 48,824 |
| Capex | 17,718 | |||||
| Non-current assets | 416,599 | 530,755 | 173,218 | 822,026 | 923,699 | 996,786 |
| Current assets | 442,622 | 446,588 | 164,103 | 503,352 | 1,937,383 | 762,286 |
| Equity | 491,223 | 738,532 | 268,914 | 1,111,951 | 1,900,997 | 535,376 |
| Non-current liabilities | 53,842 | 58,959 | 3,010 | 71,602 | 13,439 | 763,723 |
| Current liabilities | 314,156 | 179,853 | 65,397 | 141,825 | 946,630 | 459,972 |
*exchange rate of RUB/BGN as at 31.12.2015 is 40.698693
**data from the consolidated statemments for the fourth quarter